DexCom (NASDAQ: DXCM) and STAAR Surgical (NASDAQ:STAA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, institutional ownership, risk, dividends and earnings.

Profitability

This table compares DexCom and STAAR Surgical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
DexCom -10.27% -27.90% -16.20%
STAAR Surgical -6.06% -8.69% -5.03%

Volatility & Risk

DexCom has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500. Comparatively, STAAR Surgical has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for DexCom and STAAR Surgical, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DexCom 0 7 13 0 2.65
STAAR Surgical 0 0 2 0 3.00

DexCom currently has a consensus target price of $72.19, suggesting a potential upside of 45.38%. STAAR Surgical has a consensus target price of $14.00, suggesting a potential upside of 5.66%. Given DexCom’s higher probable upside, analysts clearly believe DexCom is more favorable than STAAR Surgical.

Institutional and Insider Ownership

76.5% of STAAR Surgical shares are held by institutional investors. 1.7% of DexCom shares are held by company insiders. Comparatively, 3.4% of STAAR Surgical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares DexCom and STAAR Surgical’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
DexCom $632.70 million 6.79 -$63.30 million ($0.77) -64.49
STAAR Surgical $84.48 million 6.45 -$672,999.00 ($0.11) -120.45

STAAR Surgical has higher revenue, but lower earnings than DexCom. STAAR Surgical is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Summary

STAAR Surgical beats DexCom on 9 of the 13 factors compared between the two stocks.

DexCom Company Profile

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company’s markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient’s receiver and an application on the patient’s iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).

STAAR Surgical Company Profile

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery. It makes lenses used across the world in corrective or refractive surgery, and makes lenses for use in surgery that treats cataracts. Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). As of December 30, 2016, it sold its products in more than 60 countries, with direct distribution in the United States, Canada, Japan and Spain, and independent distribution in the remainder of the world.

Receive News & Stock Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related stocks with our FREE daily email newsletter.